CRDF
Cardiff Oncology, Inc. (CRDF) ESG Analysis Analysis (2026)
Environmental
CRDF's R&D intensity is very high versus peers, which can support lower direct operating emissions intensity, but it also signals a resource-heavy development model.
The company’s minimal leverage reduces balance-sheet pressure to defer environmental investments, yet peers with larger scale may still execute more comprehensive sustainability programs.
No filing-based emissions, energy, or waste disclosures were provided, so relative environmental positioning versus peers remains difficult to verify beyond capital-allocation proxies.
Compared with diversified healthcare peers, CRDF appears more exposed to laboratory and development footprint risks, but the absence of disclosed environmental controversies limits evidence of structural weakness.
Social
CRDF's high R&D spend suggests a science-intensive workforce model, which can support talent retention, but peers with larger platforms typically disclose broader employee and community programs.
Stock-based compensation is elevated versus revenue, indicating reliance on equity incentives that can align employees, although peers often pair this with more mature disclosure on retention and culture.
No filing-based data were provided on safety, diversity, turnover, or product-access practices, limiting confidence that CRDF matches peers on broader social governance of stakeholders.
Relative to peers, CRDF appears operationally focused on specialized research talent rather than large-scale social programs, which keeps its social profile moderate rather than leading.
Governance
CRDF's very low debt-to-equity ratio indicates conservative capital structure discipline, which generally reduces creditor pressure and governance complexity versus more levered peers.
High stock-based compensation can align management with shareholders, but it also raises dilution sensitivity, and peers with stronger governance often disclose clearer long-term incentive guardrails.
No filing-based evidence was provided on board independence, audit issues, or shareholder rights, so governance strength cannot be confirmed beyond balance-sheet conservatism.
Compared with peers, CRDF looks financially disciplined but not demonstrably superior on formal governance disclosures, keeping the score in the upper-moderate range.
Overall Score
CRDF’s ESG positioning is broadly in line with peers, with conservative capital structure offset by limited disclosure on environmental and social practices.
Score Driver: Conservative Leverage And Disciplined Capital Allocation
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Cardiff Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

